These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 9636735

  • 1. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
    Mainolfi C, Maurea S, Varrella P, Alaia C, Imparato C, Alfano B, Abate G, Bazzicalupo L.
    Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
    [Abstract] [Full Text] [Related]

  • 2. Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma.
    Ömür Ö, Baran Y, Oral A, Ceylan Y.
    Diagn Interv Radiol; 2014; 20(2):185-92. PubMed ID: 24412817
    [Abstract] [Full Text] [Related]

  • 3. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ.
    Cancer; 2002 Feb 15; 94(4):879-88. PubMed ID: 11920454
    [Abstract] [Full Text] [Related]

  • 4. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U.
    Radiol Clin North Am; 2007 Jul 15; 45(4):697-709, vii. PubMed ID: 17706534
    [Abstract] [Full Text] [Related]

  • 5. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN.
    Radiology; 1997 Jun 15; 203(3):795-800. PubMed ID: 9169707
    [Abstract] [Full Text] [Related]

  • 6. Extranodal malignant lymphoma: detection with FDG PET versus CT.
    Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, Reske SN.
    Radiology; 1998 Feb 15; 206(2):475-81. PubMed ID: 9457202
    [Abstract] [Full Text] [Related]

  • 7. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
    Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K, Hayashi K, Nakamura K, Masuda K.
    Ann Nucl Med; 2002 Jul 15; 16(5):337-45. PubMed ID: 12230093
    [Abstract] [Full Text] [Related]

  • 8. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging.
    Lopci E, Burnelli R, Ambrosini V, Nanni C, Castellucci P, Biassoni L, Rubello D, Fanti S.
    Cancer Biother Radiopharm; 2008 Dec 15; 23(6):681-90. PubMed ID: 19111053
    [Abstract] [Full Text] [Related]

  • 9. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY, Kao A, Yen RF.
    Oncol Rep; 2002 Dec 15; 9(2):321-5. PubMed ID: 11836600
    [Abstract] [Full Text] [Related]

  • 10. Staging in childhood lymphoma: differences between FDG-PET and CT.
    Hermann S, Wormanns D, Pixberg M, Hunold A, Heindel W, Jürgens H, Schober O, Franzius C.
    Nuklearmedizin; 2005 Feb 15; 44(1):1-7. PubMed ID: 15711722
    [Abstract] [Full Text] [Related]

  • 11. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, Wioland M, Leverger G, Talbot JN.
    Eur J Nucl Med Mol Imaging; 2002 Sep 15; 29(9):1155-65. PubMed ID: 12192560
    [Abstract] [Full Text] [Related]

  • 12. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
    Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, Saitoh T, Handa H, Endo K, Murakami H.
    Cancer; 2007 Aug 01; 110(3):652-9. PubMed ID: 17582800
    [Abstract] [Full Text] [Related]

  • 13. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?
    Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK, Goerres GW.
    Radiology; 2004 Sep 01; 232(3):823-9. PubMed ID: 15273335
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U, Fabry U, Neuerburg J, Zimny M, Bares R, Osieka R, Büll U.
    Nuklearmedizin; 2001 Feb 01; 40(1):23-30. PubMed ID: 11373935
    [Abstract] [Full Text] [Related]

  • 15. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma.
    Kotzerke J, Guhlmann A, Moog F, Frickhofen N, Reske SN.
    Eur J Nucl Med; 1999 Jan 01; 26(1):31-8. PubMed ID: 9933659
    [Abstract] [Full Text] [Related]

  • 16. Positron emission tomography for detection and staging of malignant lymphoma.
    Buchmann I, Moog F, Schirrmeister H, Reske SN.
    Recent Results Cancer Res; 2000 Jan 01; 156():78-89. PubMed ID: 10802866
    [Abstract] [Full Text] [Related]

  • 17. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L.
    Semin Radiat Oncol; 2007 Jul 01; 17(3):190-7. PubMed ID: 17591566
    [Abstract] [Full Text] [Related]

  • 18. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D, de Wit M, Beyer W, Beese M, Lübeck M, Bücheler E, Clausen M.
    Rofo; 1998 May 01; 168(5):457-65. PubMed ID: 9617362
    [Abstract] [Full Text] [Related]

  • 19. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease.
    Paes FM, Kalkanis DG, Sideras PA, Serafini AN.
    Radiographics; 2010 Jan 01; 30(1):269-91. PubMed ID: 20083598
    [Abstract] [Full Text] [Related]

  • 20. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
    Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Hegenbart U, Irngartinger G, Oberdorfer F, van Kaick G.
    Radiologe; 1997 Jan 01; 37(1):74-80. PubMed ID: 9157479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.